Abstract:Novel bifunctional thienopyridine derivatives linked by an ester bond demonstrate simultaneous targeting of FXa and P2Y12 receptors. These compounds act as mutual prodrugs, combining anticoagulant and antiplatelet activity in a single molecule. This approach offers potential advantages in the treatment of cardiovascular disease through simplified administration and synergistic therapeutic effects. Thienopyridine derivatives are specifically designed for utilization in antithrombotic therapy to help combat cardiovascular disorders linked to thrombosis. This study introduces new thienopyridine derivatives with superior therapeutic efficacy through synergies by dual functional compounds, developed as antithrombotic agents. Through computational design, we discovered 32 compounds out of a library of 100 compounds that exhibit efficacy. The compounds are synthesized by multiple steps and subsequently purified using chromatographic procedures to achieve a purity level of >99%. Using the ADP‐induced platelet aggregation assay, we have found 4 active test compounds (ACG‐0173‐19, ACG‐0173‐37, ACG‐A‐04, and ACG‐B‐03) out of a total of 32 compounds. On the other hand, ACG‐0173‐19, ACG‐0173‐37, ACG‐A‐04, and ACG‐B‐03 have demonstrated the highest percentage activity on factor Xa (FXa) inhibition. The ACG‐A‐04 chemical exhibited the highest hydrophilicity, specifically in terms of its aqueous solubility. It had a solubility of 0.44 mg/mL in pH 5.8, 0.29 mg/L in pH 6.2, and 0.145 mg/L in pH 7.4 buffers. In comparison, the standards APX‐01 (apixaban) and PRG‐01(prasugrel) had lower hydrophilicity. Based on cytotoxicity investigations, it was determined that the test substances do not exhibit harmful effects. The results indicated that the test chemicals can undergo hydrolysis in blood plasma rather than in other organs. Among the four test drugs, ACG‐1073‐19 exhibited an unbound fraction of 44.1%, which is twice as high as the standards (apixaban). ACG‐1073‐37 demonstrates superior plasma protein binding (33.2%) compared to all other test compounds. The compounds resulted in a higher expression of CD61, CD42b, and CD62P in platelets compared to the control. The ACG‐1073‐37 molecule had a Caco‐2 permeability of 51%, which is extremely close to the Caco‐2 permeability of the control medicines (55% for APX‐01 and 62% for PRG‐01). Through the assessment of microsomal stability, it was determined that ACG‐1073‐37 and ACG‐A‐04 exhibited metabolic stability for 42.4 and 34.14 min, respectively.

Design, Synthesis and Pharmacokinetic Study of Deuterated Ticagrelor Derivatives

Clinical effect of ticagrelor administered in acute coronary syndrome patients following percutaneous coronary intervention.

Design, Synthesis and Biological Evaluation of N,N-3-phenyl-3-benzylaminopropanamide Derivatives As Novel Cholesteryl Ester Transfer Protein Inhibitor

Evaluation of efficacy and safety after replacement of methyl hydrogen with deuterium at methyl formate of Clopidogrel

Switching a Xanthine Oxidase Inhibitor to a Dual-Target Antagonist of P2Y 1 and P2Y 12 as an Oral Antiplatelet Agent with a Wider Therapeutic Window in Rats than Ticagrelor

Progress in the clinical effects and adverse reactions of ticagrelor

Novel antiplatelet agent ticagrelor

Pharmacokinetics and Tolerability of Single and Multiple Doses of Ticagrelor in Healthy Chinese Subjects

Engineered P2Y12-Overexpressing Cell-Membrane-Wrapped Nanoparticles for the Functional Reversal of Ticagrelor and Clopidogrel

Ticagrelor Versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome: A Pharmacodynamic Analysis.

Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update

Analysis of clinical application of ticagrelor, a new oral antiplatelet drug

Synthesis of new class dipeptide analogues with improved permeability and antithrombotic activity.

QSAR, structure-based pharmacophore modelling and biological evaluation of novel platelet ADP receptor (P2Y12) antagonist

Appropriate prophylactic antibiotic use in plastic surgery: the time has come.

Ticagrelor: Positive, Negative and Misunderstood Properties As a New Antiplatelet Agent

Development and validation of a UPLC-MS/MS method for simultaneous determination of vicagrel and its major metabolites in rat or human plasma: An optimized novel strategy for the stabilization of vicagrel.

Research progress of increased adenosine-mediated biological effects and adverse reactions by ticagrelor

Comparison of half- and standard-dose ticagrelor in Chinese patients with NSTE-ACS.

Effects of myricetin and quercetin on ticagrelor metabolism and the underlying mechanism

Cleavable Novel Thienopyridine Derivatives as Potent Antithrombotic Agents